Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral microbiota signatures associated with viremia and CD4 recovery in treatment-naïve HIV-1-infected patients.
Nannini G, Di Gloria L, Russo E, Sterrantino G, Kiros ST, Coppi M, Niccolai E, Baldi S, Ramazzotti M, Di Pilato V, Lagi F, Bartolucci G, Rossolini GM, Bartoloni A, Amedei A. Nannini G, et al. Among authors: sterrantino g. Microbes Infect. 2024 Jul-Aug;26(5-6):105339. doi: 10.1016/j.micinf.2024.105339. Epub 2024 Apr 16. Microbes Infect. 2024. PMID: 38636822 Free article.
Facilitators and barriers in HIV testing and continuum of care among migrant transgender women who are sex workers residing in Florence, Italy.
Lagi F, Gatteschi C, Tilli M, Zocco N, Avarello A, Bellini S, Contanessi S, Zigliani MR, Stagnitta M, Mariano L, Gazzarri E, Belloni L, Fisher AD, Bartoloni A, Sterrantino G, Ierardi F. Lagi F, et al. Among authors: sterrantino g. Int J Transgend Health. 2023 May 18;25(2):268-282. doi: 10.1080/26895269.2023.2209072. eCollection 2024. Int J Transgend Health. 2023. PMID: 38681492 Free PMC article.
Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort.
Ciccullo A, Baldin G, Cervo A, Moschese D, Lagi F, Cossu MV, Grimaldi A, Giacomelli A, Rusconi S, Sterrantino G, Borghetti A, Antinori S, Mussini C, Di Giambenedetto S. Ciccullo A, et al. Among authors: sterrantino g. J Antimicrob Chemother. 2024 Oct 30:dkae392. doi: 10.1093/jac/dkae392. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 39478330
Impact of rapid-antiretroviral therapy in a cohort of treatment-naïve migrants living with HIV in a high income setting.
Trevisan S, Gasparro G, Kiros ST, Pozzi M, Malcontenti C, Campolmi I, Paggi R, Cavallo A, Farese A, Ducci F, Meli M, Pittorru M, Bartoloni A, Sterrantino G, Lagi F. Trevisan S, et al. Among authors: sterrantino g. Int J STD AIDS. 2024 Oct;35(11):858-864. doi: 10.1177/09564624241270970. Epub 2024 Aug 6. Int J STD AIDS. 2024. PMID: 39106048
Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes.
Giammarino F, de Salazar A, Malet I, Viñuela L, Fuentes A, Saladini F, Bartolini N, Charpentier C, Lambert-Niclot S, Sterrantino G, Colao MG, Micheli V, Bertoli A, Fabeni L, Teyssou E, Delgado R, Falces-Romero I, Aguilera A, Gomes P, Paraskevis D, Santoro MM, Ceccherini-Silberstein F, Marcelin AG, Moreno C, Zazzi M, García F. Giammarino F, et al. Among authors: sterrantino g. J Infect Dis. 2024 Jun 14;229(6):1796-1802. doi: 10.1093/infdis/jiae010. J Infect Dis. 2024. PMID: 38206187
Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice.
Ciccullo A, Baldin G, Borghi V, Oreni L, Lagi F, Fusco P, Giacomelli A, Torti C, Sterrantino G, Mussini C, Antinori S, Di Giambenedetto S. Ciccullo A, et al. Among authors: sterrantino g. Int J Antimicrob Agents. 2024 Jan;63(1):107040. doi: 10.1016/j.ijantimicag.2023.107040. Epub 2023 Nov 20. Int J Antimicrob Agents. 2024. PMID: 37981074
Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
Lagi F, Giacomelli A, Borghi V, Ciccullo A, Taramasso L, Madeddu G, D'Ettorre G, Giacometti A, Ducci F, De Vito A, Pincino R, Di Giambenedetto S, Mussini C, Antinori S, Sterrantino G. Lagi F, et al. Among authors: sterrantino g. J Med Virol. 2023 Oct;95(10):e29149. doi: 10.1002/jmv.29149. J Med Virol. 2023. PMID: 37805832
Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients.
Fabbiani M, Masini M, Rossetti B, Ciccullo A, Borghi V, Lagi F, Capetti A, Colafigli M, Panza F, Baldin G, Mussini C, Sterrantino G, Farinacci D, Montagnani F, Tumbarello M, Di Giambenedetto S. Fabbiani M, et al. Among authors: sterrantino g. Viruses. 2023 May 8;15(5):1123. doi: 10.3390/v15051123. Viruses. 2023. PMID: 37243208 Free PMC article.
127 results